- Genetic medicines company Passage ( NASDAQ: PASG ) appointed William Chou CEO and a board member, effective immediately.
- Chou, most recently, served as CEO of the clinical-stage biopharmaceutical company Aruvant Sciences.
- Chou replaces interim CEO Edgar Cale, who will resign from the post and continue in his role as general counsel and corporate secretary.
- Also, Maxine Gowen will step down as interim executive chairwoman following a brief transition period and will then continue to serve as chairwoman.
- Source: Press Release
For further details see:
Passage appoints William Chou CEO